E-cigarettes potentially harmful: PET imaging shows greater lung inflammation in e-cigarette users than cigarette smokers
IMAGE: SUMMARY OF THE PILOT STUDY AND PRELIMINARY PET IMAGING FINDINGS. view more
CREDIT: IMAGE CREATED BY R WETHERILL, DEPARTMENT OF PSYCHIATRY, PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA.
Reston, VA—Electronic cigarette (e-cigarette) users have greater lung inflammation than cigarette smokers and non-smokers, according to a new study published online in The Journal of Nuclear Medicine. This study is the first to provide evidence that vaping e-liquids with e-cigarettes creates a unique inflammatory response in the lungs that is different from cigarette smoking.
E-cigarette usage has increased dramatically in the past several years, particularly among adolescents and young adults. While many assume that e-cigarettes are safer than conventional cigarettes, they can cause pulmonary inflammation and increase the risk of lung disease. In addition, their long-term safety has not been rigorously evaluated.
This is the first PET study to use a novel radiotracer, 18F-NOS, to compare lung inflammation between cigarette and e-cigarette users in vivo. Although PET imaging with 18F-FDG has been used in the past to investigate inflammation in smokers and vapers, its conclusions were limited.
“iNOS is an enzyme that is overexpressed in e-cigarette users and cigarette smokers and is associated with acute and chronic inflammatory diseases,” said Reagan Wetherill, PhD, the study’s lead author and faculty member at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. “This makes it a relevant target for molecular imaging of lung inflammation and inflammatory lung disease.”
Study participants were divided into three age- and sex-matched groups: five e-cigarette users, five cigarette smokers, and five never-smoked/vaped controls. 18F-NOS PET was performed to quantify and compare lung inflammation.
E-cigarette users showed greater pulmonary inflammation than cigarette smokers and never-smoked/vaped controls. A positive association between pulmonary and peripheral measures of inflammation was also found, suggesting that e-cigarette use may increase pulmonary inflammation.
“Having these findings provides patients with additional evidence about the potentially harmful effects of e-cigarette use on the lungs,” says Wetherill. “Our work advances what is currently known about the impacts of e-cigarette use on respiratory health and provides a better understanding of harm and harm reduction associated with e-cigarette use relative to cigarette smoking.”
Senior author and Perelman School of Medicine Department of Radiology faculty member Jacob Dubroff, MD, PhD, sees a growing role for using molecular imaging to understand the effects of electronic cigarettes. He notes, “These findings suggest molecular imaging may be uniquely poised to detect and measure the potential pathophysiologic harms associated with electronic cigarettes, which have been touted as a safer vehicle for nicotine compared to traditional combustible cigarettes.”
This study was made available online in January 2023.
The authors of “Molecular Imaging of Pulmonary Inflammation in Electronic and Combustible Cigarette Users: A Pilot Study” include Reagan R. Wetherill, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Robert K. Doot, Anthony J. Young, Hsiaoju Lee, Erin K. Schubert, Robert H. Mach, and Jacob G. Dubroff, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corinde E. Wiers, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania and Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Frank T. Leone, Comprehensive Smoking Treatment Program, Penn Lung Center, Philadelphia, Pennsylvania; and Henry R. Kranzler, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania and Crescenz VAMC, Philadelphia, Pennsylvania.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
JOURNAL
Journal of Nuclear Medicine
ARTICLE TITLE
Molecular imaging of pulmonary inflammation in electronic and combustible cigarette users: a pilot study
ARTICLE PUBLICATION DATE
19-Jan-2023
COI STATEMENT
Dr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; recipient of grant funds and medication supplies from Alkermes for an investigator-initiated study; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka; and a holder of U.S. patent 10,900,082 titled: "Genotype-guided dosing of opioid agonists," issued 26 January 2021. Drs. Dubroff, Doot, and Mach have received support from the Michael J. Fox Foundation.
No comments:
Post a Comment